Lakefront Biotherapeutics NV (LKFT34)

Overview

Lakefront Biotherapeutics NV is a biotechnology company specializing in the development of innovative medicines with a primary focus on oncology and immunology. The company operates mainly in the United States and Europe, working to address significant health challenges associated with various cancers and autoimmune diseases. Lakefront Biotherapeutics has a robust pipeline of products, which demonstrates its commitment to advancing cutting-edge therapies in the biotech space. The company has established collaboration agreements with Gilead Sciences, Inc., which enhances its research and development capabilities. Originally incorporated in 1999 under the name Galapagos NV, it rebranded to Lakefront Biotherapeutics NV in May 2026, reflecting its evolving mission and focus in the biotherapeutics landscape. Headquartered in Mechelen, Belgium, the company is well-positioned to make impactful contributions to global healthcare.

Products and Services

• GLPG3667

  This product is currently undergoing a phase 2 clinical trial targeting dermatomyositis and systemic lupus erythematosus. GLPG3667 aims to provide new therapeutic options for patients suffering from these debilitating autoimmune conditions, focusing on effective and safe outcomes for improved patient care.

• GLPG5101

  GLPG5101 is a CD19 CAR-T product candidate that is uniquely manufactured at the point-of-care. It is currently being evaluated in a phase 1/2 clinical trial for patients with relapsed/refractory non-Hodgkin lymphoma. This innovative approach aims to harness the body’s immune system to target cancer cells more effectively.

• GLPG5301

  This BCMA CAR-T product candidate is also produced at point-of-care and is in phase 1/2 clinical trials for relapsed/refractory multiple myeloma. GLPG5301 represents another step forward in the application of CAR-T therapy, aimed at providing a tailored and focused attack on malignant cells in multiple myeloma patients.